Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg
NCT ID: NCT02600468
Last Updated: 2017-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
671 participants
OBSERVATIONAL
2013-09-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL
NCT02600455
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis
NCT03331393
Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study
NCT01694693
Dose Escalation With Remicade® and Orencia®
NCT01141413
Korean Post-marketing Surveillance for Orencia®
NCT01583244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who use ORENCIA
Patients who use ORENCIA for the approved indications and who at the start of treatment
Orencia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orencia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have available HAQ data
* Have available DAS28-ESR or DAS28- CRP data
* Have no past or present history of malignancies
* Are expected to be followed up for 3 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-516
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.